ABANZA, a company in advanced soft tissue repair solutions, announced the completion of its Pre-Series A funding round, raising $5 million. This funding round was led by a family office specializing in medical device investments and private investors. These funds will be used to accelerate the U.S. launch of ABANZA’s innovative Soft Tissue Fixation product line, including the WasherCap and WasherCap Mini.
This funding marks a significant advance toward achieving ABANZA’s mission to revolutionize soft tissue repair with its patented technology. And ABANZA’s technology addresses major challenges in the soft tissue repair market by enhancing fixation strength regardless of patient bone quality and minimizing graft displacement after surgery.
The WasherCap Fixation System received FDA clearance for fixation of soft tissue grafts, including tendons and ligaments, during surgical procedures like in Anterior Cruciate Ligament (ACL) reconstruction of the knee and has been used by a select group of surgeons in a preliminary launch. The company is also preparing to introduce the WasherCap Mini, catering to a wider range of applications including knee, hand, wrist, and elbow repairs.
ABANZA is expanding its field sales team to work with leading orthopedic specialists across key U.S. markets. And this expansion will evolve with increased staffing, production capacity, and educational initiatives for physicians.
ABANZA is prepared for a growth phase in the U.S., with the WasherCap Fixation System leading its product rollout. And this launch marks the beginning of a comprehensive strategy to meet the needs in soft tissue repair and establish ABANZA as a key player in this sector.
KEY QUOTES:
“Having used this device, I’ve noted its exceptional performance in eliminating residual graft laxity right from the start. It’s very easy to use and ideal for cases where fixation and laxity is a concern; especially when using adjustable button fixation”.
- Nirav Amin, an Orthopedic Sports Medicine specialist in Orange County, California
“This funding represents a pivotal moment for our entry into the U.S. market with the WasherCap™ Soft Tissue Fixation System. The WasherCap product is the first in a series of innovative solutions we plan to introduce for soft tissue repair. We are fortunate to have engaged with an outstanding group of investors, many of whom bring deep healthcare expertise and valuable connections to our venture.”
- Juan Abascal, CEO of ABANZA
